Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2017 August;83(8) > Minerva Anestesiologica 2017 August;83(8):878-87

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,623


eTOC

 

EXPERTS’ OPINION  FREEfree


Minerva Anestesiologica 2017 August;83(8):878-87

DOI: 10.23736/S0375-9393.17.11884-5

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Recent antiseizure medications in the Intensive Care Unit

Cindy ORINX, Benjamin LEGROS, Nicolas GASPARD

Department of Neurology, Erasme Hospital, Université Libre de Bruxelles, Bruxelles, Belgium


FULL TEXT  


BACKGROUND: Seizures and status epilepticus (SE), both clinical and subclinical, are frequent in critically ill patients. The list of available antiseizure medications (ASMs) is expanding and now includes older and widely used drugs as well as more recent medications with a better safety and pharmacokinetics profile.
METHODS: We review a selection of recent publications about the indications and administration of ASMs in critical care for the prophylaxis and treatment of seizures and SE, focusing on recent ASMs available as intravenous formulation and emphasizing pharmacokinetics and safety issues in relation to several aspects of critical illness.
RESULTS: Levetiracetam, lacosamide and more recently brivaracetam, represent interesting alternatives to older ASMs, mostly due to a more favorable safety and pharmacokinetic profile. Low-quality studies suggest that this profile results in better tolerability in treated patients. Ketamine might represent a useful addition in our anesthetic armamentarium for refractory SE, due to its different mechanism of action and cardiovascular properties. Little evidence is available however to support the prophylactic use of ASMs in critically ill patients, except in specific settings (traumatic brain injury and subarachnoid hemorrhage). Head-to-head studies comparing recent and older ASMs in the treatment of acute seizures and SE are ongoing or awaiting publication. Administration of ASMs to critically ill patients needs to be adapted to organ dysfunction, and especially to renal dysfunction for recent drugs.
CONCLUSIONS: Recent ASMs and could represent better treatment choices in critically ill patients than older ones but this needs to be confirmed in randomized controlled studies. In general, further studies are required to clarify the indications and optimal use of ASMs in the critical care setting.


KEY WORDS: Seizures - Status epilepticus - Pharmacokinetics - Critical care - Intensive Care Units - Lacosamide

top of page

Publication History

Issue published online: July 17, 2017
Article first published online: May 11, 2017
Manuscript accepted: April 19, 2017
Manuscript revised: April 14, 2017
Manuscript received: December 20, 2016

Cite this article as

Orinx C, Legros B, Gaspard N. Recent antiseizure medications in the Intensive Care Unit. Minerva Anestesiol 2017;83:878-87. DOI: 10.23736/S0375-9393.17.11884-5

Corresponding author e-mail

nicolas.gaspard@erasme.ulb.ac.be